Background Co-occurring genomic alterations identified downstream main oncogenic
drivers have become more evident since the introduction of next-generation sequencing …

PURPOSE Next-generation sequencing (NGS) has enabled the detection of concomitant
driver alterations in non–small cell lung cancer (NSCLC). However, the magnitude and …

Background/Aim: Non-small cell lung cancer (NSCLC) patients with activating somatic
mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine …

The molecular pathways which promote lung cancer cell features have been broadly
explored, leading to significant improvement in prognostic and diagnostic strategies …

Introduction Epidermal growth factor receptor (EGFR) 19del and L858R mutation are known
as “common mutations” in non-small cell lung cancer (NSCLC) and predict sensitivities to …

Introduction EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor
(TKI) treatment. Because co-occurring genomic alterations might describe different …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …

This study aimed to explore the clinical significance of genomics features including tumor
mutation burden (TMB) and copy number alteration (CNA) for advanced EGFR mutant lung …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

Common sensitizing mutations in epidermal growth factor receptor (cEGFR), including exon
19 deletions (19-Del) and exon 21 L858R substitution, are associated with high sensitivity to …